New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Check below for free stories on LPCN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
09:12 EDTLPCNLipocine management to meet with Jefferies
Meeting to be held in New York on July 23 hosted by Jefferies.
July 15, 2014
16:03 EDTLPCNLipocine announces issuance of U.S. patent for LPCN 1021
Lipocine announced that the USPTO has issued U.S. patent number 8,778,922, entitled "Steroidal Compositions." This patent relates to pharmaceutical compositions having testosterone undecanoate. The patent is expected to provide protection through January 2029 for LPCN 1021.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use